Vitamin e-loaded pla- and plga-based core-shell nanoparticles: synthesis, structure optimization and controlled drug release

Norbert Varga, Árpâd Turcsânyi, Viktória Hornok, Edit Csapó

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The (±)-α-Tocopherol (TP) with vitamin E activity has been encapsulated into biocompatible poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) carriers, which results in the formation of well-defined nanosized (d ~200–220 nm) core-shell structured particles (NPs) with 15–19% of drug loading (DL%). The optimal ratios of the polymer carriers, the TP active drug as well as the applied Pluronic F127 (PLUR) non-ionic stabilizing surfactant, have been determined to obtain NPs with a TP core and a polymer shell with high encapsulation efficiency (EE%) (69%). The size and the structure of the prepared core-shell NPs as well as the interaction of the carriers and the PLUR with the TP molecules have been determined by transmission electron microscopy (TEM), dynamic light scattering (DLS), infrared spectroscopy (FT-IR) and turbidity studies, respectively. Moreover, the dissolution of the TP from the polymer NPs has been investigated by spectrophotometric measurements. It was clearly confirmed that increase in the EE% from ca. 70% (PLA/TP) to ca. 88% (PLGA65/TP) results in the controlled release of the hydrophobic TP molecules (7 h, PLA/TP: 34%; PLGA75/TP: 25%; PLGA65/TP: 18%). By replacing the PLA carrier to PLGA, ca. 15% more active substance can be encapsulated in the core (PLA/TP: 65%; PLGA65/TP: 80%).

Original languageEnglish
Article number0357
JournalPharmaceutics
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 2019

    Fingerprint

Keywords

  • Controlled drug release
  • Core-shell nanoparticles
  • Drug delivery
  • PLA
  • PLGA
  • Tocopherol
  • Vitamin E

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this